Allergan's Fishing For Deals, But Don't Expect A Big Catch
This article was originally published in The Pink Sheet Daily
Executive Summary
Allergan will use its $36bn in after-tax cash and equity from the sale of its generics business to Teva to reduce debt, buy back shares of its stock, and to acquire companies or assets, but don't expect Allergan to catch any big fish in its deal-making net.
You may also be interested in...
Pfizer Buys Anacor With Blockbuster Ambitions For Crisaborole
Pfizer agreed to acquire Anacor for roughly $5.2bn, with the expectation that its late-stage PDE4 inhibitor crisaborole, under review by FDA for the treatment of atopic dermatitis, will generate peak sales of more than $2bn.
Allergan Seeks Opportunities To Dominate In Key Therapeutic Areas
CEO Brent Saunders reviewed past deals, but not the present negotiations with Pfizer, during R&D day.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.